Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 10/20 | 0.41 |
| ▸ | CTSS | P25774 | 8/20 | 0.41 |
| ▸ | CTSB | P07858 | 6/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9799149 | 0.76 | HTT (0.31) | HTT | |
| SCHEMBL18855896 | 0.73 | CTSK (0.53) | CTSKCTSSCTSBMAPTHTT | |
| SCHEMBL7292726 | 0.67 | RAB9A (0.36) | NPC1RAB9A | |
| SCHEMBL12958892 | 0.67 | — | — | |
| SCHEMBL16661734 | 0.66 | L3MBTL1 (0.38) | NPC1RAB9A | |
| SCHEMBL28944683 | 0.66 | TRPM8 (0.39) | NPC1RAB9A | |
| SCHEMBL19817080 | 0.65 | TRPM8 (0.36) | NPC1RAB9A | |
| SCHEMBL7955691 | 0.65 | — | — | |
| SCHEMBL21952207 | 0.64 | — | — | |
| SCHEMBL3169784 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116437919-B | Methods of treating metastasis with cathepsin C inhibitors | 中国科学院上海营养与健康研究所 | 2024-04-02 | — | — | CN | disclosed |
| US-20230321056-A1 | Methods for Treating Metastasis with Cathepsin C Inhibitors | Shanghai Institute of nutrition and health, Chinese Academy of Sciences (CN) | 2023-10-12 | — | — | US | disclosed |
| EP-4210706-A1 | METHODS FOR TREATING METASTASIS WITH CATHEPSIN C INHIBITORS | Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences (CN) | 2023-07-19 | — | — | EP | disclosed |
| CN-116437919-A | Methods of treating metastasis with cathepsin C inhibitors | 中国科学院上海营养与健康研究所 | 2023-07-14 | — | — | CN | disclosed |
| WO-2022053019-A1 | METHODS FOR TREATING METASTASIS WITH CATHEPSIN C INHIBITORS | Shanghai Institute of nutrition and health, Chinese Academy of Sciences (CN) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321056-A1 | Methods for Treating Metastasis with Cathepsin C Inhibitors | MMP8, CTSS, CTSF | CTSK 9/4885CTSS 2/4885CTSB 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.